<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504894</url>
  </required_header>
  <id_info>
    <org_study_id>0701008933</org_study_id>
    <secondary_id>K08GM083213</secondary_id>
    <nct_id>NCT00504894</nct_id>
  </id_info>
  <brief_title>Neuroimaging the Effects of Intravenous Anesthetic on Amygdala Dependent Memory Processes</brief_title>
  <acronym>Amygdala</acronym>
  <official_title>Neuroimaging the Effects of Intravenous Anesthetic on Amygdala Dependent Memory Processes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves 60 healthy volunteers aged between 18 and 50 recruited from the general&#xD;
      community. It involves doing a set of simple memory tests while inside a fMRI machine. The&#xD;
      subject is given a very low dose of an anesthetic drug intravenously while in the scanner.&#xD;
      The subject then sees a sequence of pictures on a screen, and presses a button if they&#xD;
      remember seeing the picture before. While this is happening, the scanner will be capturing&#xD;
      images that tell us what parts of the brain are active. Hypothesis: patterns of hippocampal&#xD;
      and amygdala activation during the encoding and retrieval of memory,as measured by fMRI, will&#xD;
      be altered by intravenous anesthetics such that suppression of hippocampal and amygdala&#xD;
      activities will be dissociable. This dissociation pattern will be different between the drugs&#xD;
      propofol and thiopental.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Subclinical doses of propofol produce anterograde amnesia, characterized by an&#xD;
      early failure of memory consolidation. It is unknown how propofol affects the&#xD;
      amygdala-dependent emotional memory system, which modulates consolidation in the hippocampus&#xD;
      in response to emotional arousal and neurohumoral stress. We present an event-related&#xD;
      functional magnetic resonance imaging study of the effects of propofol on the emotional&#xD;
      memory system in human subjects.&#xD;
&#xD;
      Methods: Sixty healthy subjects were randomized to receive propofol, at an estimated brain&#xD;
      concentration of 0.90 μgml-1, thiopental, at an estimated brain concentration of 3.0 μgml-1,&#xD;
      or placebo. During drug infusion, emotionally arousing and neutral images were presented in a&#xD;
      continuous recognition task, while blood-oxygen-level-dependent activation responses were&#xD;
      acquired. After a drug-free interval of 2 h, subsequent memory for successfully encoded items&#xD;
      was assessed. Imaging analysis was performed using statistical parametric mapping and&#xD;
      behavioural analysis using signal detection models.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    One study drug (thiopental) became commercially unavailable&#xD;
  </why_stopped>
  <start_date type="Actual">March 2007</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood-oxygen-level-dependent Significant Activation Cluster</measure>
    <time_frame>for 90 minutes after the drug/placebo was commenced</time_frame>
    <description>Three anatomical regions for which there was an a priori mechanistic hypothesis were assessed using standard small volume correction: (i) the amygdala, bilaterally; (ii) the hippocampus, bilaterally; and (iii) the parahippocampus, bilaterally. Using single-tailed t tests, a priori regions were reported as significant if the initial uncorrected voxel-wise P value was &lt; 0.001, and then the P value was &lt; 0.05 after family-wise error correction for multiple comparisons in the hypothesized anatomical region. For non-hypothesized regions outside the medial temporal lobe, findings were reported as significant if the initial uncorrected voxel-wise P value was &lt; 0.001, and then the P value was &lt; 0.05 after family-wise error correction for multiple comparisons across the whole brain. Clusters containing voxel maxima at these thresholds are reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood-oxygen-level-dependent Significant Activation Cluster for Positive Sequential Memory</measure>
    <time_frame>for 90 minutes after the drug/placebo was commenced</time_frame>
    <description>Three anatomical regions for which there was an a priori mechanistic hypothesis were assessed using standard small volume correction: (i) the amygdala, bilaterally; (ii) the hippocampus, bilaterally; and (iii) the parahippocampus, bilaterally. Using single-tailed t tests, a priori regions were reported as significant if the initial uncorrected voxel-wise P value was &lt; 0.001, and then the P value was &lt; 0.05 after family-wise error correction for multiple comparisons in the hypothesized anatomical region. For non-hypothesized regions outside the medial temporal lobe, findings were reported as significant if the initial uncorrected voxel-wise P value was &lt; 0.001, and then the P value was &lt; 0.05 after family-wise error correction for multiple comparisons across the whole brain. Clusters containing voxel maxima at these thresholds are reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given in low dose to gauge subject's responses to visual stimuli.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol given at 0.90 μgml-1 to gauge subject's responses to visual stimuli.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thiopental</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thiopental given at 3.0 μgml-1 to gauge subject's responses to visual stimuli.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.</description>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiopental</intervention_name>
    <description>A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.</description>
    <arm_group_label>Thiopental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age b/w 18 and 50&#xD;
&#xD;
          -  right-handed&#xD;
&#xD;
          -  minimum of high school education&#xD;
&#xD;
          -  fluent in English&#xD;
&#xD;
          -  normal vocabulary&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  any significant medical/psychiatric comorbidity&#xD;
&#xD;
          -  deficit in vision or hearing that would impede the study&#xD;
&#xD;
          -  allergies to any of the study drugs, to soybeans, or eggs.&#xD;
&#xD;
          -  history of head trauma&#xD;
&#xD;
          -  family history of major psychiatric illness&#xD;
&#xD;
          -  body mass index &gt; 30 kg/m2&#xD;
&#xD;
          -  claustrophobia&#xD;
&#xD;
          -  prior exposure to IAPS pictures&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  permanent metal objects anywhere in the body&#xD;
&#xD;
          -  a personal/family history of any porphyria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kane Pryor, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 19, 2007</study_first_submitted>
  <study_first_submitted_qc>July 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <results_first_submitted>February 28, 2017</results_first_submitted>
  <results_first_submitted_qc>April 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2017</results_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>N/A healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thiopental</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo given in low dose to gauge subject's responses to visual stimuli.&#xD;
Placebo: A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.</description>
        </group>
        <group group_id="P2">
          <title>Propofol</title>
          <description>Propofol give at 0.90 μgml-1 to gauge subject's responses to visual stimuli.&#xD;
Propofol: A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.</description>
        </group>
        <group group_id="P3">
          <title>Thiopental</title>
          <description>Thiopental give at 3.0 μgml-1 to gauge subject's responses to visual stimuli.&#xD;
Thiopental: A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>fMRI technical problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Infusion technical problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>poor subject data</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo given in low dose to gauge subject's responses to visual stimuli.&#xD;
Placebo: A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.</description>
        </group>
        <group group_id="B2">
          <title>Propofol</title>
          <description>Propofol given at 0.90 μgml-1 to gauge subject's responses to visual stimuli.&#xD;
Propofol: A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.</description>
        </group>
        <group group_id="B3">
          <title>Thiopental</title>
          <description>Thiopental give at 3.0 μgml-1 to gauge subject's responses to visual stimuli.&#xD;
Thiopental: A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" lower_limit="22" upper_limit="29"/>
                    <measurement group_id="B2" value="25" lower_limit="23" upper_limit="26"/>
                    <measurement group_id="B3" value="24" lower_limit="22" upper_limit="32.5"/>
                    <measurement group_id="B4" value="25" lower_limit="22" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Blood-oxygen-level-dependent Significant Activation Cluster</title>
        <description>Three anatomical regions for which there was an a priori mechanistic hypothesis were assessed using standard small volume correction: (i) the amygdala, bilaterally; (ii) the hippocampus, bilaterally; and (iii) the parahippocampus, bilaterally. Using single-tailed t tests, a priori regions were reported as significant if the initial uncorrected voxel-wise P value was &lt; 0.001, and then the P value was &lt; 0.05 after family-wise error correction for multiple comparisons in the hypothesized anatomical region. For non-hypothesized regions outside the medial temporal lobe, findings were reported as significant if the initial uncorrected voxel-wise P value was &lt; 0.001, and then the P value was &lt; 0.05 after family-wise error correction for multiple comparisons across the whole brain. Clusters containing voxel maxima at these thresholds are reported.</description>
        <time_frame>for 90 minutes after the drug/placebo was commenced</time_frame>
        <population>Of the 20 placebo subjects recruited, 3 subjects' data was excluded due to technical problems or poor quality.&#xD;
Of the 21 propofol subjects recruited, 3 subjects' data was excluded due to technical problems, poor quality, or subject withdrawal.&#xD;
Of the 19 thiopental subjects recruited, no subjects' data was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo given in low dose to gauge subject's responses to visual stimuli.&#xD;
Placebo: A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Propofol give at 0.90 μgml-1 to gauge subject's responses to visual stimuli.&#xD;
Propofol: A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.</description>
          </group>
          <group group_id="O3">
            <title>Thiopental</title>
            <description>Thiopental give at 3.0 μgml-1 to gauge subject's responses to visual stimuli.&#xD;
Thiopental: A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood-oxygen-level-dependent Significant Activation Cluster</title>
          <description>Three anatomical regions for which there was an a priori mechanistic hypothesis were assessed using standard small volume correction: (i) the amygdala, bilaterally; (ii) the hippocampus, bilaterally; and (iii) the parahippocampus, bilaterally. Using single-tailed t tests, a priori regions were reported as significant if the initial uncorrected voxel-wise P value was &lt; 0.001, and then the P value was &lt; 0.05 after family-wise error correction for multiple comparisons in the hypothesized anatomical region. For non-hypothesized regions outside the medial temporal lobe, findings were reported as significant if the initial uncorrected voxel-wise P value was &lt; 0.001, and then the P value was &lt; 0.05 after family-wise error correction for multiple comparisons across the whole brain. Clusters containing voxel maxima at these thresholds are reported.</description>
          <population>Of the 20 placebo subjects recruited, 3 subjects' data was excluded due to technical problems or poor quality.&#xD;
Of the 21 propofol subjects recruited, 3 subjects' data was excluded due to technical problems, poor quality, or subject withdrawal.&#xD;
Of the 19 thiopental subjects recruited, no subjects' data was excluded.</population>
          <units>BOLD significantly activated clusters</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Amygdala</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Amygdala</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Hippocampus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Hippocampus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Parahippocampal Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Parahippocampal Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood-oxygen-level-dependent Significant Activation Cluster for Positive Sequential Memory</title>
        <description>Three anatomical regions for which there was an a priori mechanistic hypothesis were assessed using standard small volume correction: (i) the amygdala, bilaterally; (ii) the hippocampus, bilaterally; and (iii) the parahippocampus, bilaterally. Using single-tailed t tests, a priori regions were reported as significant if the initial uncorrected voxel-wise P value was &lt; 0.001, and then the P value was &lt; 0.05 after family-wise error correction for multiple comparisons in the hypothesized anatomical region. For non-hypothesized regions outside the medial temporal lobe, findings were reported as significant if the initial uncorrected voxel-wise P value was &lt; 0.001, and then the P value was &lt; 0.05 after family-wise error correction for multiple comparisons across the whole brain. Clusters containing voxel maxima at these thresholds are reported.</description>
        <time_frame>for 90 minutes after the drug/placebo was commenced</time_frame>
        <population>Of the 20 placebo subjects recruited, 3 subjects' data was excluded due to technical problems or poor quality.&#xD;
Of the 21 propofol subjects recruited, 3 subjects' data was excluded due to technical problems, poor quality, or subject withdrawal.&#xD;
Of the 19 thiopental subjects recruited, no subjects' data was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo given in low dose to gauge subject's responses to visual stimuli.&#xD;
Placebo: A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Propofol give at 0.90 μgml-1 to gauge subject's responses to visual stimuli.&#xD;
Propofol: A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.</description>
          </group>
          <group group_id="O3">
            <title>Thiopental</title>
            <description>Thiopental give at 3.0 μgml-1 to gauge subject's responses to visual stimuli.&#xD;
Thiopental: A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood-oxygen-level-dependent Significant Activation Cluster for Positive Sequential Memory</title>
          <description>Three anatomical regions for which there was an a priori mechanistic hypothesis were assessed using standard small volume correction: (i) the amygdala, bilaterally; (ii) the hippocampus, bilaterally; and (iii) the parahippocampus, bilaterally. Using single-tailed t tests, a priori regions were reported as significant if the initial uncorrected voxel-wise P value was &lt; 0.001, and then the P value was &lt; 0.05 after family-wise error correction for multiple comparisons in the hypothesized anatomical region. For non-hypothesized regions outside the medial temporal lobe, findings were reported as significant if the initial uncorrected voxel-wise P value was &lt; 0.001, and then the P value was &lt; 0.05 after family-wise error correction for multiple comparisons across the whole brain. Clusters containing voxel maxima at these thresholds are reported.</description>
          <population>Of the 20 placebo subjects recruited, 3 subjects' data was excluded due to technical problems or poor quality.&#xD;
Of the 21 propofol subjects recruited, 3 subjects' data was excluded due to technical problems, poor quality, or subject withdrawal.&#xD;
Of the 19 thiopental subjects recruited, no subjects' data was excluded.</population>
          <units>BOLD significantly activated clusters</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Amygdala</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Amygdala</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Hippocampus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Hippocampus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Parahippocampal Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Parahippocampal Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo given in low dose to gauge subject's responses to visual stimuli.&#xD;
Placebo: A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.</description>
        </group>
        <group group_id="E2">
          <title>Propofol</title>
          <description>Propofol give at 0.90 μgml-1 to gauge subject's responses to visual stimuli.&#xD;
Propofol: A low dose of propofol 0.90 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.</description>
        </group>
        <group group_id="E3">
          <title>Thiopental</title>
          <description>Thiopental give at 3.0 μgml-1 to gauge subject's responses to visual stimuli.&#xD;
Thiopental: A low dose of thiopental 3.0 μgml-1, given intravenously while the subject is shown visually stimulating images in an MRI machine.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kane Pryor</name_or_title>
      <organization>Weill Cornell Medicine</organization>
      <phone>(212) 746-2953</phone>
      <email>kap9009@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

